Updated from 11:04 a.m. EDT

IT outsourcing firm iGate ( IGTE) has turned up the pressure on IBM ( IBM) and Hewlett-Packard ( HPQ) to acquire disgraced Indian tech shop Satyam Computer, according to reports.

Fremont, Calif.-based iGate, which confirmed last week that it was exploring a majority position in Satyam, has been negotiating with private equity firm TPG Capital as a possible investment partner, according to a report Sunday by Dow Jones.

The report also mentions that India-based competitor Tech Mahindra is interested in a possible deal. In addition to IBM and H-P, the list of potential bidders or financing partners also reportedly includes Fidelity Investments and buyout shop KKR.

Satyam has been forced to sell a majority stake in its business in the wake of a devastating alleged book-cooking scheme by founder Ramalinga Raju. In January, Raju, who resigned, revealed that the scandal involved years of inflated profit reports and a bogus cash pool of $1 billion.

Observers say rival technology service contractors like IBM and H-P would be keen to acquire Satyam, not so much for its business operations, but more for its roster of worldwide clients.

iGate CEO Phaneesh Murthy has said that a possible bidding price for Satyam would be about 90 cents a share, according to TV reports Monday. The bid would be well below the current price.

Satyam shares were down 4.7% to $2.83 in recent trading.

If you liked this article you might like

IGate (IGTE) Marked As A Barbarian At The Gate

IGate (IGTE) Marked As A Barbarian At The Gate

IGate (IGTE) Showing Signs Of Being Strong And Under The Radar

IGate (IGTE) Showing Signs Of Being Strong And Under The Radar

European Stocks Edge Up From 3-Month Lows; Bayer Sells Diabetes Division

European Stocks Edge Up From 3-Month Lows; Bayer Sells Diabetes Division

Water-Logged And Getting Wetter Stock Of The Day: IGate (IGTE)

Water-Logged And Getting Wetter Stock Of The Day: IGate (IGTE)

Nasdaq Backs Off Record High as Biotech Drags Markets Lower

Nasdaq Backs Off Record High as Biotech Drags Markets Lower